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Abstract
Background: DNA methylation is a widely studied epigenetic mechanism known to correlate with
gene repression and genomic stability. Development of sensitive methods for global detection of
DNA methylation events is of particular importance.
Results: We here describe a technique, called modified methylation-specific digital karyotyping
(MMSDK) based on methylation-specific digital karyotyping (MSDK) with a novel sequencing
approach. Briefly, after a tandem digestion of genomic DNA with a methylation-sensitive mapping
enzyme and a fragmenting enzyme, short sequence tags are obtained. These tags are amplified,
followed by direct, massively parallel sequencing (Solexa 1G Genome Analyzer). This method
allows high-throughput and low-cost genome-wide DNA methylation mapping. We applied this
method to investigate global DNA methylation profiles for widely used breast cancer cell lines,
MCF-7 and MDA-MB-231, which are representatives for luminal-like and mesenchymal-like cancer
types, respectively. By comparison, a highly similar overall DNA methylation pattern was revealed
for the two cell lines. However a cohort of individual genomic loci with significantly different DNA
methylation status between two cell lines was identified. Furthermore, we revealed a genome-wide
significant correlation between gene expression and the methylation status of gene promoters with
CpG islands (CGIs) in the two cancer cell lines, and a correlation of gene expression and the
methylation status of promoters without CGIs in MCF-7 cells.
Conclusion: The MMSDK method will be a valuable tool to increase the current knowledge of
genome wide DNA methylation profiles.
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Background
One key component of the cancer epigenome is an altered
DNA methylation pattern by global hypomethylation and
promoter localized hypermethylation [1]. These methyla-
tion changes can result in an alteration in structure and
function of DNA, such as unwanted activation of repeat
elements, abnormal transcriptional regulation of genes
involved in cancer initiation and progression, and predis-
position to genomic instability through disruption of
chromosome replication control [2,3].
Numerous studies have paid attention to the difference of
DNA methylation profiles between malignant breast cells
and normal control, regardless of their origins [4,5].
Molecular subtype taxonomy of breast cancers and breast
cancer cell lines is more and more important, and the
identified new biomarkers that inflect cell origin might be
promising targets for disease treatment [6-8]. MCF-7 and
MDA-MB-231 are widely used breast cancer cell lines in
cancer research [9]. Both cell lines were established from
metastatic cells in pleural effusions collected from two
individual ductal invasive breast cancers [9,10]. MCF-7 is
classified as a luminal (epithelium)-like cell line with rel-
atively low invasive potential, whereas MDA-MB-231 is a
mesenchymal-like cell line which is highly invasive
[6,10]. Comparison of the two cell lines in terms of DNA
copy number variation (CNV) and gene expression pro-
files have been performed [6,11]. However, a comprehen-
sive picture of DNA methylation patterns, DNA copy
number alterations and gene expression levels genome
wide for the two cell lines remains to be established.
A detailed exploration of the role of DNA methylation in
tumorigenesis depends on sensitive methods to precisely
describe DNA methylation states genome wide. Methyla-
tion-specific digital karyotyping (MSDK) is one such pow-
erful method [12,13], which combines the use of
methylation-sensitive restriction enzyme digestion and
sequencing by a SAGE-like method to achieve genome-
wide DNA methylation maps [12,13]. However, this tech-
nique is limited by a relatively low throughput and a high
cost of sequencing. Solexa 1G Genome Analyzer is a new
generation sequencer which can perform massively paral-
lel signature sequencing. Thus, it has been applied in epi-
genetic studies to improve currently existing techniques
[14-16]. In the present study, we establish a method,
modified methylation-specific digital karyotyping
(MMSDK) on the basis of the combination of original
MSDK [12,13] and the new sequencing technique using
Solexa 1G Genome Analyzer. In the original MSDK
method ditags are produced followed by clone sequenc-
ing. In MMSDK tags are directly amplified by PCR using a
pair of universal primers and subsequently sequenced
using a Solexa sequencer. Finally, tags (reads) are mapped
back to the human genome. We chose MCF-7 and MDA-
MB-231 as representatives for luminal-like and mesenchy-
mal-like subtypes, respectively, and used these cell lines
for comparative analysis by MMSDK, array comparative
genomic hybridization (aCGH) and gene expression
microarray analysis to explore the correlation between
DNA methylation, genomic stability and gene expression.
We demonstrate that MMSDK is a genome-wide, high-
throughput and cost-effective method to analyze DNA
methylation in large genomes such as the human and that
MMSDK can be used to reveal connections between
genomic, epigenetic and transcriptional features.
Methods
Biological material
The two breast cancer cell lines MCF-7 and MDA-MB-231
were obtained from the European Collection of Cell Cul-
ture. Cells were routinely cultured in DMEM medium sup-
plemented with 10% fetal bovine serum and collected
during the growth phase before confluence.
MMSDK
MSDK [12,13] is a modification of the original digital
karyotyping technique [17]. In this study, we developed
MMSDK as a combination of the original MSDK and Sol-
exa sequencing (Fig 1). The procedures prior to tag con-
catenation were similar to those described originally for
MSDK [12,13]. Briefly, DNA was isolated from the cell
lines using DNeasy® Blood & Tissue Kit (QIAGEN) follow-
ing manufacturer's protocol. Genomic DNA was digested
with methylation-sensitive mapping enzyme MluI (New
England Biolabs). MluI has two CpG sites in its recogni-
tion sequence, ACGCGT, and therefore its recognition site
is preferentially located in CpG islands (CGIs). Digested
DNA was ligated to biotinylated linkers and fragmented
by NlaIII (New England BioLabs) cleavage. Because MluI
only cuts unmethylated regions, binding of DNA frag-
ments to streptavidin-conjugated magnetic beads will sep-
arate the unmethylated and methylated fragments.
Because of a potential risk that digested DNA without
biotinylated linkers may be unspecifically bound by
streptavidin-conjugated beads, we performed a parallel
control experiment instead using DNA fragments without
biotinylated linkers. Bound DNA was ligated to another
linker (N) containing a MmeI restriction enzyme recogni-
tion site, and then digested with MmeI  (New England
Biolabs) that generates short sequence tags (16–17 bp,
due to enzyme cut floating). Instead of the concatenation
of tags and clone sequencing, tags were ligated with P7
linker and amplified by PCR with primers N and P7. To
avoid the bias from PCR, amplification was stopped after
15 cycles. The sequences of the linkers and primers are
available in Additional file 1.
Clone sequencing
Conventional clone sequencing was carried out prior to
Solexa sequencing. Briefly, PCR products from the two
cell lines and the control were ligated with T-easy vectorBMC Genomics 2009, 10:223 http://www.biomedcentral.com/1471-2164/10/223
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The strategy of MMSDK Figure 1
The strategy of MMSDK. Schematic presentation of the MMSDK method. Details of the method are described in the text.BMC Genomics 2009, 10:223 http://www.biomedcentral.com/1471-2164/10/223
Page 4 of 15
(page number not for citation purposes)
(Promega), and transformed into competent DH5α bacte-
ria (Takara). Plasmid DNA was purified from 19 clones of
each PCR product (MCF-7, MDA-MB-231 and the con-
trol) and analyzed by conventional sequencing.
Sequencing using Solexa 1G Genome Analyzer
Sequencing-By-Synthesis (SBS) was performed for the
generation of tags using Illumina Cluster Generation
(Illumina) and 1G Genome Analyzer (Illumina) accord-
ing to the manufacturer's instructions [18]. All reagents
for the sequencing process were purchased from Illumina
Inc. Briefly, the PCR product was ligated with adaptors
(Sequences of adaptors and PCR primers are available in
Additional file 1). DNA fragments were amplified by PCR
using Phusion polymerase (Finnzymes). PCR products
were purified using a QIAquick MiniElute Kit (Qiagen).
We performed cluster generation and standard cycle of
sequencing on the Illumina cluster station and 1G ana-
lyzer following the manufacturer's instructions. Finally,
the tag sequences were stored as libraries for each cell line.
Tag mapping and statistical analysis
We extracted 16–17 bp tags from all reads obtained by
sequencing. Because of the risk that the length of 16–17
bp is too short to obtain high confidence whole genome
wide mapping, we developed a mapping process based on
the simulation of enzyme cutting of the DNA. The human
genome sequence and mapping information (Santa Cruz
human genome assembly (hg18), March 2006) was
downloaded from the University of California, Santa Cruz
Genome Bioinformatics Site [19] and a virtual MluI and
NlaIII cutting DNA fragment library was constructed as
follows: we located the predicted MluI sites, identified the
nearest NlaIII sites in both directions and sampled the
derived DNA fragments as the reference for mapping.
MAQ (Mapping and Assembly with Qualities) was used to
map all tags back to this library [20,21]. We defined high-
confidence mapped tags as those with a mapping quality
score more than 20. In order to identify genes neighboring
the MluI sites (to correlate their expression with the degree
of methylation), we removed all virtual tags with low con-
fidence mapping results (mapping quality score < 20) in
the genome to ensure unambiguous mapping of the data.
As the description in MAQ manual, a tag with mapping
quality 20 should have 1% error rate in principle and a tag
with quality higher than 20 should have an alignment
error rate below 0.1% on average. SNPs and sequencing
errors are considered in calculating this score. For the
analysis of the repeat families and genome wide overview
scanning, we considered all tags mapped back to the
genome with a tolerance of low-confidence mapping. We
used all mapped tags for determination of their chromo-
some location, then normalized tag numbers to address
the potential problem of uneven total tag numbers
between the libraries. The normalized libraries were used
for comparison of the two cell lines and calculation of P-
values. To analyze the significance of the differences in
DNA methylation between two cell lines, Z-score test was
used to calculate the P-value for each MluI  site in the
genome by means of pair-wise comparison. False discov-
ery rate (FDR) control was added for the correction of the
P-values to address the multiple comparisons problem of
the high-throughput techniques. FDR controls the
expected proportion of incorrectly rejected null hypothe-
ses (type I error). It is a less conservative procedure for
comparison, with greater power than familywise error rate
(FWER) control, at a cost of increasing the likelihood of
type I error. The corresponding gene annotations are from
the National Center for Biotechnology Information "The
Reference Sequence (RefSeq)" database [22].
qPCR
A qPCR assay was designed for the validation of the meth-
ylation results from MMSDK (see Additional file 2).
Briefly, genomic DNA from the two cell lines was equally
divided into two parts. One portion was digested with
MluI and the other portion served as an undigested con-
trol. The digested and undigested DNA samples were
amplified by qPCR using locus-specific primers that flank
a given MluI restriction site in the human genome. The
methylation state of a given genomic locus is determined
in a manner that depends on restriction digestion of
unmethylated sequences using MluI and the resulting fail-
ure to PCR amplify the digested fragements. Only the
fragements containing methylated MluI site are protected
from the digestion and, thus, serve as template for ampli-
fication. All PCR primers were designed to generate frag-
ments of about 100 bp. A genomic region containing a
HindIII cutting site (AAGCTT) but no MscI cutting site
(TGGCCA) was selected as control. An equal amount of
this template was digested by HindIII or MscI. Through
quantitive comparison between the two sets of PCR prod-
ucts, the methylation state of the MluI site for a given
genomic locus will be identified. The selected genomic
loci for qPCR validation and their corresponding primer
sequences are available online (see Additional file 3).
Bisulfite treated PCR and clone sequencing
We applied MethyPrimer website service to design
bisulfite treated PCR primers. Genomic DNA in both
breast cancer cells was conversed using EpiTect Bisulfite
Kit (Qiagen), followed by PCR amplification, catalyzed by
Taq clone polymerase (Invitrogen). The PCR program is as
follows: denature at 95°C for 4 min, followed by 5 cycles:
denature at 95°C for 30 sec, anneal at 56°C (variable
according to primers' Tm) for 90 sec, and extend for 2
min, followed by 25 cycles: denature at 95°C for 30 sec,
anneal at 56°C (variable according Tm for primers) for 90
sec, and extend for 90 sec. PCR products were purified
using GFX PCR DNA and Gel Band Purification Kit (GE
Healthcare) and performed transformation using TOPO
TA Cloning for Sequencing Kit (Invitrogen). Single colo-BMC Genomics 2009, 10:223 http://www.biomedcentral.com/1471-2164/10/223
Page 5 of 15
(page number not for citation purposes)
nial bacteria were picked up from LB plate for culturing.
Plasmid DNA was purified using GenElute Plasmid Mini-
prep Kit (Sigma) from bacteria cluture. Plasmid DNA for
each genomic locus was sequenced using dideoxy chain
termination method with ABI 3730XL 96-capillary
sequencer. Sequencing was performed by MWG in Ebers-
berg. The outcome of bisulfite clone sequencing result for
each genomic locus was visualized by CpG viewer [23].
The information of the genomic loci and the primers is
available in Additional file 3.
Array CGH
Array CGH was performed as described previously [24].
Briefly, CytoChip v2.0 (BlueGnome) with BAC clone
human DNA fragments, representing the whole genome
with 0.5-Mb resolution on average, was used to detect copy
number variation (CNV) for both cell lines. A dye-swap
method was applied in the array CGH. Cell line sample and
reference (pooled healthy females) DNA was labeled with
Cy3-dCTP and Cy5-dCTP (Amersham Biosciences), respec-
tively, using a random priming method with the labeling
kit BioPrime® DNA labeling system (Invitrogen), and the
reverse labeling for sample and reference DNA was per-
formed as well. The mixture of the differentially labeled cell
line DNA (22~24 ug) and reference DNA (22~24 ug),
together with 230 ul (1 mg/ml) Cot-1 DNA (Invitrogen) for
blocking hybridization to repetitive sequences, was ethanol
precipitated and resuspended in hybridization mix (50%
formamide, 10% dextran sulfate, 2XSSC, 1%–4% (v/v)
SDS, heering sperm DNA (10 mg/ml) (Invitrogen), and
salmon sperm DNA (10 mg/ml) (GIBCOBRL, Life Technol-
ogies)) to a total volume 130 ul. After denaturing at 75°C
for 15 min, the DNA mixture was incubated at 37°C for 1.5
hours to allow regression annealing of repetitive sequences.
The pre-hybridization, hybridization and washing were
performed using HS 4800 Pro hybridization station
(TECAN). After washing with PBS, the hybridization mix
was added to the array. Tumor and reference DNA co-
hybridize the denatured target DNA on the CytoChip slide
with relative kinetics dependent on CNV. After hybridiza-
tion, the slide was washed with a series of solutions: PBS
and 0.05% Tween20 at 37°C for 3 min; 0.1 × SSC at 54°C
for 3 min; PBS and 0.05% Tween20 at 23°C for 80 sec; 0.2
× SSC for 30 sec. Finally, the slide was dried by blowing
nitrogen. The array was imaged in a GenePix 4000 B laser
scanner (Axon Instruments). After optimizing exposure
time, the array was scanned in Cy3 and Cy5 channels,
respectively. Two single-channel 16-bit images were com-
bined for analysis using the image-analysis software "Blue-
Fuse" v3.5 (BlueGenome). The thresholds for deletion and
amplification were -0.299 and 0.299, respectively, by
default. The breakpoints in the genome were determined
by the flanking clones that located the boundaries of the
aberration regions. The BAC clone positions information is
based on NCBI Build 36.
Gene expression profiling
Total RNA was extracted from frozen cell lines with TRI
Reagent (Sigma) according to the manufacturer's proto-
col. The integrity of the extracted RNA extract was checked
by agarose gel electrophoresis, and the concentration of
RNA was estimated by spectrophotometry. Gene expres-
sion profiles were obtained by array hybridization using
Human U133 Plus 2.0 (Affymetrix), which can estimate
the expression level of 47,400 transcripts and variants.
cRNA preparations, hybridizations, washing and detec-
tion were performed at Aros Biotechnology, Aarhus, Den-
mark, according to the manual of Affymetrix.
Results
MMSDK
To elucidate genome wide DNA methylation patterns we
developed a modified version of MSDK, MMSDK. To dis-
tinguish methylated from unmethylated cytosines we
selected the Mlu1 restriction enzyme which is a methyla-
tion sensitive six-bp cutter. For further DNA fragmenta-
tion and establishment of a second anchor for linker
ligation, DNA also was digested with NlaIII which is a
methylation insensitive restriction enzyme. In silico analy-
ses showed that there are 21309 recognition sites for the
MluI restriction enzyme in the human genome. We per-
formed a digital digestion of the human genome with
MluI and NlaIII under the hypothesis that all cytosines are
unmethylated. We notice the presence of 369 MluI frag-
ments lacking internal NlaIII recognition sites. The distri-
bution of the lengths of the theoretically generated MluI/
NlaIII  fragments is presented in Additional file 4. The
majority of fragments are shorter than 1000 bp, with a fre-
quency peak at 50–150 bp. There are 3154 MluI recogni-
tion sites in CGIs defined by three criteria (GC content >
50%, ratio of the observed CpGs to the expected CpGs >
0.6, length > 400 bp), accounting for 14.8% of all MluI
recognition sites in the human genome. Furthermore, our
approach also enables us to determine the methylation
state of CpGs in repeat sequences. According to Repeat-
masker [25], 353 (1.66%) of the MluI sites are located
within repeat sequences in the human genome.
The detailed protocol for the MMSDK procedure is
described in the Methods section. Prior to large-scale Sol-
exa sequencing, we performed clone sequencing to check
the outcome of MMSDK. A total of 57 clones (19 each
from MCF-7, MDA-MB-231, and the control) were
selected for sequencing. 18 clones from MCF-7 and 19
clones from MDA-MB-231 presented unique human
genomic sequences with the expected CATG motif in the
end. All sequences from the 19 clones from the control
solely contained linker sequence or less than 12 bp
inserted sequence without CATG motif. By the Solexa
sequencing in MMSDK, we obtained 5432906 and
5636928 sequenced tags with 16–17 bp length fromBMC Genomics 2009, 10:223 http://www.biomedcentral.com/1471-2164/10/223
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MCF-7 and MDA-MB-231 cells, respectively (see Addi-
tional file 4). More than 94% of the tags obtained from
both cell lines could be mapped back to MluI recognition
sites in the human genome. All information of the
obtained MMSDK libraries for the two examined cell lines
is available in Additional file 5. Our method allows us to
reveal significantly different methylation of individual
genomic loci. By comparison of methylation libraries
from the two cell lines, we identified the individual
genomic loci that have significantly different DNA meth-
ylation status (FDR P-value < 0.05) in the two cell line
libraries (see Additional file 5).
Overview of the DNA methylation profiles in the two 
cancer cell lines
At first, we compared the methylation profiles of promot-
ers, introns, exons and CGIs (not located to known pro-
moter sequences) for both cancer cell lines using a T-test
statistical method (Table 1). The two cell lines showed
generally similar DNA methylation states in the examined
genomic category of sites. This is in agreement with anal-
ysis by Shann et al. examining DNA methylation in MDA-
MB-231 and MCF-7 cells by a different technical approach
[4]. In an alternative analysis, we collected the genomic
loci with significantly different methylation states
(FDR<0.01) between the two cell lines. These genomic
sites were then divided into different groups according to
their genomic category (Table 2). Finally, we compared
the methylation states for the different genome categories
between the two cell lines using T-test (Table 2). Except
for the group of genomic sites representing introns, the
rest of the genomic categories had similar DNA methyla-
tion profiles in the two cell lines.
Our MMSDK method also allows investigation of the
DNA methylation status for repeat sequences. As
described above, a T-test was performed for the compari-
son of the distribution of unmethylated sites in different
repeat sequence categories in the two cancer cell lines. The
summary of the collected tags information in repeat
sequences for the cell lines is presented in Fig 2. Notably,
a significant difference between two cell lines in the meth-
ylation level of long interspersed nuclear elements (LINE/
L1) was observed (Fig 2).
Validation of MMSDK results with qPCR
In order to validate the results of MMSDK by an alterna-
tive method, we randomly selected a cohort of 12
genomic loci to test their DNA methylation states by a
qPCR based method (see Methods section). The informa-
tion on the selected genomic loci is provided in Addi-
tional file 3. Of the 7 loci with a relatively high number of
tags in MCF-7 cells the qPCR data were consistent with the
MMSDK data for 5 loci (see Additional file 6). Of the 5
loci with a relatively low number of tags in MCF-7 cells
the qPCR data were consistent with the MMSDK data for
4 (see Additional file 6). For MDA-MB-231 genomic DNA
analysis, a general correlation between MMSDK data and
the qPCR analysis was also present albeit with some more
inconsistencies between the two methods. Thus, qPCR
analysis largely confirmed the MMSDK results, but we
notice that genomic amplifications, efficiency of enzyme
digestion, and bias from PCR can result in differences
between the two methods.
Validation of MMSDK results with bisulfite treated PCR 
and clone sequencing
The methylation statuses of the five MluI genomic loci were
confirmed by bisulfite treated PCR and clone sequencing.
These five randomly selected genomic loci are representative
for the following situations in our study: high-level methyl-
ated sites for both cell lines (genomic loci 1, 2a and 2b);
Table 1: Comparison of the methylation states in various genomic categories
High confidence mapped tags All mapped tags
Site counts1 P-value2 Mean4 of MCF-7 Mean of MDA-MB-
231
P-value3 Mean of MCF-7 Mean of MDA-MB-
231
No CGI 596 0.8928 200.1946 194.615 0.7313 412.307 386.2217
Promoter CGI 1042 0.2108 501.2428 403.7937 0.09058 738.3695 593.3216
Intron 8213 0.9325 111.504 107.5048 0.8821 236.1427 228.3417
Exon 937 0.6431 63.10886 56.21106 0.7668 200.3436 186.15013
CGI(No promoter) 2113 0.9173 158.5939 156.5405 0.4425 325.3417 304.564
Table 1 presents a comparison of the methylation states of promoters (including the promoters with CGIs and without CGIs), introns, exons and 
CGIs (no promoters) for both cell lines using T-test statistical method, which provides an overview of the difference of the methylation state 
between two cell lines. 1 The information of the number of sites in different genomic categories is presented. 2–3 The statistical results of the 
difference of methylation states in different genomic categories between two cell lines are presented, considering high confidence mapped tags and 
all mapped tags, respectively. 4 The mean of the number of tags for the corresponding cell line in a given genomic category.BMC Genomics 2009, 10:223 http://www.biomedcentral.com/1471-2164/10/223
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Table 2: Comparison of the methylation states based on significantly different individual genomic sites
High confidence mapped tags All mapped tags
Site counts5 P-value Mean of MCF-7 Mean of MDA-MB-
231
P-value Mean of MCF-7 Mean of MDA-MB-
231
No CGI 12 0.8585 524.3333 617.5263 0.9704 791.1667 768.7776
Promoter CGI 17 0.2384 1578.882 550.6183 0.2505 2038.7647 850.4476
Intron 52 0.008962 350.1538 1286.1792 0.01392 562.4423 1503.848
Exon 15 0.378 854.0667 396.7598 0.3564 1090.0667 518.7343
CGI(No promoter) 27 0.3531 470.037 896.2317 0.4785 912.926 1292.6098
The individual genomic sites with significantly different number of tags between two cell lines were collected and classified to the corresponding 
genomic categories. Then a T-test statistical analysis was performed to test the difference of the methylation states of promoters (including the 
promoters with CGIs and without CGIs), introns, exons and CGIs (no promoters) between both cell lines. 5. The number of individually 
significantly different genomic sites involved for a give category is shown. The meanings of the P-value and mean in Table 2 are the same as in Table 
1.
Distribution of MluI sites in repeat sequences and summary of sequence tag information Figure 2
Distribution of MluI sites in repeat sequences and summary of sequence tag information. The distribution of MluI 
recognition sites in different classes of repeat sequences is presented in the top pie chart, and the bottom table summarizes the 
counting result of the tags collected for different classes of repeat sequences of the MCF-7 and MDA-MB-231 cell lines.BMC Genomics 2009, 10:223 http://www.biomedcentral.com/1471-2164/10/223
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high-level unmethylated sites for both cell lines (genomic
locus 3) and the sites with relatively higher methylated status
in one cell line than the other (genomic locus 4). There are 6
and 7 clones presenting methylated for genomic locus 1 in
MCF-7 and MDA-MB-231, respectively, (according to 50 tags
and 12 tags for genomic locus 1 in MCF-7 and MDA-MB-
231, respectively). Similarly, all 7 clones showed methylated
in both cell lines in genomic loci 2a and 2b (according to 10
tags in both genomic loci 2a and 2b in both cell lines). All 7
clones presented unmethylated in both cell lines in genomic
loci 3 (according to 7082 and 7546 tags in MCF-7 and MDA-
MB-231, respectively). Six clones were unmethylated and 7
clones methylated in MCF-7 and MDA-MB-231, respectively
(according to 4514 and 96 tags collected in MCF-7 and
MDA-MB-231, respectively). Thus, bisulfite treated PCR and
clone sequencing result also largely confirmed the reliability
of MMSDK. The result of bisulfite treated genomic sequenc-
ing is presented in Additional file 7.
Array CGH
The profiles of genomic CNV for the MCF-7 and MDA-
MB-231 cell lines are shown in Fig 3 and in Additional
file 8. The dye-swap method robustly confirmed aberra-
tions. MCF-7 and MDA-MB-231 cells both have overt
genomic instability. The main genomic aberrations in
MCF-7 are deletions on 1p, 6q, 8p, 11q, 13q, 16q, 18q
and chrX, and amplifications on 1q, 8q, 9p, 17q and
20q. In contrast, amplifications on 6p, 8q, 11q, 12q and
19p, and deletions on 2q, 3q, 6q, 7q, 8p, 12p, 13p 15p,
18q and chrX were presented in MDA-MB-231. The dele-
tion and amplification regions accounted for 33.78%
and 8.34% in the whole genome in MDA-MB-231,
respectively. For MCF-7 cells, the percentages of the dele-
tion and amplification regions in the genome were
19.58% and 14.58%, respectively. The breakpoints in
the genome for two cell lines were revealed by means of
identification of the color-change points (points flanked
by two adjacent DNA fragments indicating different
CNV) in Fig 3. Fragile sites (cytogenetically defined) are
also indicated on the chromosomes (Fig 3). In our study,
20% and 22% of the genome breakpoints were located
in the neighborhood of common fragile sites in MCF-7
and MDA-MB-231, respectively.
Gene expression
The expression levels of 47,400 transcripts and variants were
screened with Affymetrix microarray technology for both cell
lines. There were 2345 transcripts having significantly
increased expression in MCF-7 cells compared to MDA-MB-
231 cells. 328 of these transcripts were also described in the
study of Charafe-Jauffret et al. defining a gene expression
profile in luminal-like breast cancer cellular subtypes [6].
The expression of 2157 transcripts was increased in MDA-
MB-231 cells compared to MCF-7 cells. 387 of these tran-
scripts were also described in the study of Charafe-Jauffret et
al. to define a gene expression profile in mesenchymal-like
cellular subtypes [6]. The gene expression data for the two
cell lines and a description of the genes with significantly dif-
ferent expressions between the two cell lines are available in
Fig 3 Additional file 5, Additional file 9 and Additional file
10. The microarray data have been deposited in gene expres-
sion omnibus GEO database [26]. The GEO accession
number is GSE12199.
Combinatory analysis of DNA methylation state, genomic 
stability and gene transcription
We performed genome-wide joint analysis of DNA meth-
ylation, genomic stability and gene transcription based on
the three levels of global features revealed by MMSDK,
aCGH and gene expression microarray analysis, respec-
tively. We counted the number of tags from MMSDK and
mapped them to the human genome including all pre-
dicted CpG islands (CGIs), considering MluI and NlaIII
recognition site locations. Taking chromosome 1 as an
example (Fig 3), the information of the numbers of tags,
CNV status, and the gene expression level is displayed in
the corresponding genomic loci on the displayed chromo-
some. The length of the bars labeled with blue and dark
yellow in Fig 3 represents the quantitation of high-confi-
dence mapped tags and all mapped tags, respectively. The
length of the bars labeled with orange shows the extent of
gene expression. The detailed information for all chromo-
somes of both cell lines is available in Additional file 8.
The methylation profile for most genomic loci is very sim-
ilar in both cell lines. Thus, the bars frequently show sym-
metric patterns in the figure.
The correlation between the methylation state of DNA
fragments and their CNV was investigated (see Additional
file 11). As illustrated in the plot, CNV seems to be inde-
pendent of the DNA methylation state. By statistical anal-
ysis, we did not find any overall correlation between these
two features in our study (data not shown).
Furthermore, we explored the relationships between the
methylation state of promoters, first exons and introns
and the corresponding gene expression pattern. Signifi-
cant correlations between the methylation state of pro-
moters with CGIs and the corresponding gene expression
were identified in MCF-7 (R2  = 0.1461032, P-value:
4.845e-06) as well as in MDA-MB-231 (R2 = 0.1238432,
P-value: 0.0001093), respectively. Additionally, we found
a similar significant correlation between the methylation
state of the promoters lacking CGIs and gene expression
in MCF-7 (R2 = 0.14512, P-value: 0.0007437). Interest-
ingly, we did not find such a correlation in MDA-MB-231
cells (R2 = 0.06501603, P-value: 0.1324). No significant
correlation was found between gene expression and the
methylation of the first exon and intron for either of the
cell lines in our study (data not shown). The plots of geneBMC Genomics 2009, 10:223 http://www.biomedcentral.com/1471-2164/10/223
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The methylation profile, gene expression profile and DNA copy number variation of loci on Chromosome 1 Figure 3
The methylation profile, gene expression profile and DNA copy number variation of loci on Chromosome 1. 
Chromosome 1 was selected as a representative of the chromosome set. Similar information for the other chromosomes is 
presented in Additional file 8. A diagram of chromosome 1 is located in the middle. The common fragile sites are symmetrically 
indicated with thin solid black lines (the rare fragile sites marked with blue). The corresponding data for MCF-7 and MDA-MB-
231 are presented to the left and the right sides of the chromosome, respectively. The DNA copy number variation, gene 
expression and methylation status are shown consecutively. For DNA copy number variation, green, red and mild yellow mean 
amplification, deletion and no change, respectively. The length of the red bars that are vertical to the chromosome indicates 
the expression level for the corresponding genes. The length of bars located the most outside of the figure represents the 
methylation extent for the corresponding MluI sites on the chromosome. Blue indicates tags mapped with high confidence 
(mapping quality more than 20) and yellow represents all mapped tags.BMC Genomics 2009, 10:223 http://www.biomedcentral.com/1471-2164/10/223
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Correlations between gene expression and DNA methylation Figure 4
Correlations between gene expression and DNA methylation. Figure A and B present the plots of the relationships 
between the gene expression and the methylation of promoters with CGI, promoters without CGI, exons, and introns for 
MCF-7 and MDA-MB-231 cells, respectively. On the X-axis scale, the degree of methylation for each spot is calculated as the 
number of tags for a given site divided by the average number of tags for all MluI sites. Similarly, the degree of gene expression 
on the Y-axis scale is calculated as the expression value for a given gene divided by the average expression value for all genes. 
Both the methylation and expression values are log-transformed.BMC Genomics 2009, 10:223 http://www.biomedcentral.com/1471-2164/10/223
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expressions and methylation profiles of the different
sequence categories (CGIs promoters, first exons and
introns) are presented in Fig 4.
The original data including array CGH, clone sequencing
and bisulfate PCR sequencing are deposited in our public
website "Snap": http://snap.humgen.au.dk/
paper_20090331/. Solexa sequencing results for both cell
lines can be provided on request.
Discussion
Advantages of MMSDK
The combination of bisulfite modification and sequenc-
ing is the method of choice for methylation mapping in
the Epigenome Project [27,28]. However, the high cost,
labor-requirements and limitations of DNA fragment
length (usually less than one kilo-base) hamper the appli-
cation of this method in most laboratories. MSDK, as
another sequence-based method, can exactly identify dif-
ferently methylated sites genome-wide according to the
selected enzyme(s), without the requirements of complex
primer design, variable bisulfite modification and large-
scale sequencing [12,13]. Compared to microarray-based
assays, MSDK can analyze repeat sequences that exceed
the dynamic detection range or show cross-hybridization
in array analysis [29]. Furthermore, sequence-based meth-
ods seem to be more sensitive than microarray-based
methods, because the former can directly detect unmeth-
ylated sequences at the single-base level, whereas the latter
identify methylation state through capture of fluorescence
signals by hybridization. However, the original MSDK is
relatively low-throughput, labor-intensive and expensive
due to the limitation of the sequencing approach [13]. To
address these issues, we developed MMSDK, employing
the Solexa 1G Analyzer. This new sequencer can produce
1 Gigabase of sequence per run (one run consists of 8
lanes, and each lane is expected to yield up to 5 million
tags (reads)). Moreover, it allows 48-hour unattended
operation. Therefore, this approach dramatically increases
throughput for a relatively low cost. We anticipate that
MMSDK will pave the way for comprehensive use of
sequencing in DNA methylation studies.
The sequencing results validated the affinity between
biotinylated linker and streptavidin conjugated beads,
showing that the collection of methylated DNA fragments
is specific and reliable. By the validations with a qPCR
based and bisulfite treated PCR and clone sequencing
methods, the reliability of the MMSDK method could be
largely confirmed, although some variations were
observed. The reasons for these quantitative variations
between the outcomes from MMSDK and qPCR and
bisulfite clone sequencing based methods might be due to
imperfect cleavage by MluI and/or a bias derived from the
PCR amplification used in MMSDK and a bias from qPCR
itself (for qPCR), as well as a random selection of clones
(for bisulfite clone sequencing). Our present study dem-
onstrated MMSDK using MluI enzyme as an example. In
practice, this method can easily be expanded to achieve a
more comprehensive map of quantitative methylation
profiles by using a variety of methylation sensitive restric-
tion enzymes in individual or combinatory formats.
Overview of the distribution of unmethylated sites for 
MCF-7 and MDA-MB-231 cells
Our present study showed a general similarity of the meth-
ylation profiles for promoters (with and without CGIs),
exons, introns, and CGIs (excluding promoters) in the
MCF-7 and MDA-MB-231 cell lines. However differences
were present in introns (note that only 52 sites were ana-
lyzed in this study) indicated a significantly different distri-
bution of unmethylated sites between the two cell lines.
The small number of MluI recognition sites in this analysis
could be a source of bias and the tendency to lesser meth-
ylation of introns in MDA-MB-231 cells needs further
examination. The overall similarity of the distribution of
unmethylated sites between two cell lines in our study is
consistent with the results from Shann et al. [4]. They com-
pared the distribution of unmethylated sites with respect to
the positions of promoter, 1st exon, 1st intron, inner region
of gene, and regions containing no transcribed sequence in
MCF-7, MDA-MB-231, and normal human tissue genomes.
In their study, a highly similar methylation pattern in MCF-
7 and MDA-MB-231 was identified. However, this pattern
was significantly different from those patterns identified in
normal breast tissues [4].
Impact of DNA methylation on genomic stability and gene 
expression
Regional DNA hypermethylation and global hypomethyl-
ation seem to be involved in different stages of breast can-
cer development [30,31]. Functional outcomes of
hypomethylation include the transcriptional up-regula-
tion of proto-oncogenes, and increased genomic instabil-
ity [32]. A correlation between hypomethylation status of
repeat sequences and genomic instability was reported in
previous studies [33]. Only a small proportion of the MluI
sites in the human genome are located in repeat
sequences, but we collected many tags from these repeat
sequences, showing that they are present in an unmethyl-
ated state. Considering the obvious genomic instability in
both cell lines, our results support a correlation between
hypomethylation in repeat elements and genome insta-
bility. Gilbert et al reported that LINE-1 retrotransposition
could result in significant deletions of genomic sequence
[34]. Hypomethylation of LINE-1 in tumor cells in com-
parison to normal tissues was previously described
[33,35,36], and a decrease in the level of methylation of
LINE-1 was suggested to activate transcription and
increase retrotransposition events [33]. Notably, althoughBMC Genomics 2009, 10:223 http://www.biomedcentral.com/1471-2164/10/223
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a considerable number of tags were found in both the
MCF-7 and MDA-MB-231 cell lines, there was a signifi-
cant higher LINE-1 demethylation level in MDA-MB-231
compared to MCF-7. A higher percentage of deletions was
observed among the observations in MDA-MB-231 cells
(33.78%) compared to MCF-7 cells (19.58%). These
observations could lead support to the idea that
hypomethylation of LINE-1 has an impact on global
genome deletion processes in tumors.
Common fragile sites are sites of frequent breakages and
rearrangements in tumor cells [37]. In our study, 20% and
22% genome breakpoints were found to be located in the
neighborhood of common fragile sites in MCF-7 and
MDA-MB-231, respectively. It is hypothesized that breaks
at fragile sites may serve as signatures of stalled or delayed
replication in tumor cells, aggravated by deficiencies in
the S-phase and G2/M checkpoints or associated repair
genes during tumorigenesis [37,38].
Most cytosines within CpG dinucleotides are methylated
in the human genome, but some remain unmethlyated in
CpG islands [39]. Regional hypermethylation in tumori-
genesis typically occurs in CGIs located in gene promoter
regions [32]. Results of hypermethylation include sup-
pression of tumor suppressor genes and chromatin con-
densation [32]. In the genome-wide analyses presented
here, we indeed find that gene expression shows a
stronger correlation with the methylation state of the cor-
responding CGIs in promoters than those in other com-
ponents of the genes. Rivenbark and his colleagues
reported that putative genes whose expression is under
methylation-dependent regulation include genes lacking
typical CGIs, based on their study on the MCF-7 cell line
using a microarray-based methylation method [40].
Besides a significant correlation between gene expression
and the methylation of the promoters with CGIs, we also
find a significant correlation between gene expression and
the methylation of the promoters without CGIs in this cell
line, supporting Rivenbark's observations [40]. However,
a similar correlation did not appear in the analysis in
MDA-MB-231 cells suggesting cell type specific differ-
ences. We also noticed that the correlation of gene expres-
sion and methylation state of CGIs in promoter regions is
not very high in both cell lines, although it is significant
and stronger than the other correlations. A reasonable
explanation is that not all genes of the genome are subject
to DNA methylation-dependent regulation, and that gene
regulation mainly depends on multiple regulation mech-
anisms.
Luminal-like and mesenchymal-like cellular subtypes
Breast cancer classification has recently evolved with the
definition of molecular subtypes with different progno-
sis based on large-scale gene expression profiling [7,41]
and protein expression profiling [42,43]. Breast cancer
cell lines have also been classified in molecular subtypes
according to their expression profiles [7,44]. Recently,
based on the analysis of the gene expression profile in 31
breast cell lines, "luminal" and "mesenchymal" subtype
features were revealed [6]. MCF-7 and MDA-MB-231 cell
lines both originate from pleural effusion metastatic
cells from ductal invasive breast carcinomas [10]. How-
ever, MCF-7 expresses large numbers of markers typical
of the luminal epithelium, presenting a "luminal-like"
phenotype, whereas MDA-MB-231 is presenting a "mes-
enchymal-like" phenotype [10]. MCF-7 and MDA-MB-
231 are among the most commonly used breast cancer
cell lines in laboratories. As a result, MCF-7 and MDA-
MB-231 had 5774 and 1157 citations, respectively, with
some of the highest citation frequencies compared with
other breast cancer cell lines in the past decade of cancer
research [9]. Therefore, MCF-7 and MDA-MB-231 cells
are regarded as good representatives to use for compre-
hensive analyses of the similarity and difference in bio-
logical nature between luminal-like and mesenchymal-
like cancer subtypes. Accordingly, the DNA methylation
patterns of these two cell lines revealed in this study
might be useful for other researchers.
Charafe-Jauffret et al, identified 629 transcripts that are
expressed preferentially in the group of luminal-like
breast cancer cell lines, and 680 transcripts preferentially
expressed in the group of mesenchymal-like cell lines [6].
In our expression study, 328 transcripts were identified
with significantly higher expression in MCF-7 cells and
overlapping with the luminal subtype gene list from
Charafe-Jauffret's study [6]. 387 transcripts were identi-
fied with significantly higher expression in MDA-MB-231
cells which were also identified in the mesenchymal-like
subtype gene list in Charafe-Jauffret's study [6]. Accord-
ingly, to some extent, our expression results correlate the
findings of the luminal and mesenchymal subtype makers
in Charafe-Jauffret's study. Thus we investigated whether
the DNA methylation status of CGIs correlate with gene
expression for genes involved in determining the luminal
and mesenchymal profiles of the two cell lines. We ana-
lyzed the DNA methylation states only for genes identi-
fied both in our expression analysis and in the analysis by
Charafe-Jauffret. From these 715 transcripts we could
deduce the CGI methylation status for 42 genes and derive
candidate genes whose CGI hypomethylation level is con-
sistent with the expression level by comparison of the two
cell lines. These candidate genes includes ARSJ, C10orf56,
FLRT2, IGF2BP3 and  PDGFC  representing luminal cell
expression, and MCF2L, ARRDC4, PREX1, TSGA2,
CTNND2, TPD52L1, TRPS1 and  RBM35A  representing
mesenchymal cell expression. If CGI methylation indeedBMC Genomics 2009, 10:223 http://www.biomedcentral.com/1471-2164/10/223
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is involved in the transcriptional regulation of these can-
didate genes will be an important issue for our future
research. Thus, our study indicates the possibility to use
MMSDK not only to determine methylation profiles
between different genome samples but also to correlate
DNA methylation profiles with gene expression and gene
CNV data. From the basis of this study the future employ-
ment of methylation-sensitive enzyme(s) that have more
recognition sites in the human genome could provide
more detailed information of DNA methylation profiles
of individual genes.
Conclusion
We have developed an improved approach, MMSDK, to
explore DNA methylation patterns genome wide and
applied this approach to the analysis of two representatives
of luminal-like and mesenchymal-like cell lines. The data
derived from MMSDK allows epigenomic profiling that can
be combined with genomic CNV and gene expression data
produced by microarray-based high-throughput
approaches to achieve a comprehensive "Omics"-level
analysis. We also addressed the impact of DNA methyla-
tion on gene expression for the two cancer cell lines and
identified potential candidate genes whose expression
might be regulated by methylation of their CGIs.
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